Steric Stabilization of Liposomes Containing Amphotericin B: A Future Direction in Antifungal Therapy?
In the past ten years lipid formulations of amphotericin B (AMB) have been developed by the pharmaceutical industry with the primary aim of reduction of AMB’s toxicity. At present, three different industrially produced AMB-lipid formulations are available, with substantial lower toxicity than conventional AMB (Fungizone®). One formulation is AmBisome®, and is discussed in chapter 13 of this book.
KeywordsAntifungal Activity Invasive Fungal Infection Liposomal Amphotericin Mononuclear Phagocyte System Uninfected Mouse
Unable to display preview. Download preview PDF.
- 1.Adler-Moore JP, Proffitt RT. Development, characterization, efficacy and mode of action of AmBisome®, a unilammelar formulation of amphotercin B. J Liposome Res 1993; 3: 429–450.Google Scholar
- 2.Bakker-Woudenberg IAJM, Lokerse AF, Ten Kate MT, Mouton JW, Woodle MC, Storm G: Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae infected lung tissue. J Infect Dis 1993; 168: 164–171.Google Scholar
- 3.AmBisome® Liposomal Amphotericin B, Product Monograph. NeXstar Pharmaceuticals, Inc. 1994.Google Scholar
- 4.Van Etten EWM, Van Vianen W, Tijhuis RHG, Storm G, and Bakker-Woudenberg IAJM. Sterically stabilized amphotericin B-liposomes: toxicity and biodistribution in mice. J Control Release 1995; 37: 123–129.Google Scholar
- 5.Van Etten EWM, Otte-Lambillion M, Van Vianen W, Ten Kate MT, BakkerWoudenberg IAJM. Biodistribution of liposomal amphotericin B (AmBisome) versus amphotericin B-desoxycholate (Fungizone) in immunocompetent uninfected mice as well as in leucopenic mice infected with Candida albicans. J Antimicrob Chemother 1995; 35:509-519.Google Scholar
- 6.Van Etten EWM, Ten Kate MT, Stearne-Cullen LET, Bakker-Woudenberg IAJM: Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice. Antimicrob Agents Chemother 1995; 39: 1954–1958.Google Scholar
- 7.Leenders ACAP, De Marie S. The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia 1996; 10: 1570–1575.Google Scholar
- 8.Van Etten EWM, Snijders SV, Verbrugh HA, Bakker-Woudenberg IAJM. Efficacy of pegylated long circulating amphotericin B-liposomes versus AmBisome® in the treatment of systemic candidiasis in leukopenic mice in relation to the severity of infection. (manuscript in preparation)Google Scholar
- 9.Leenders ACAP, de Marie S, Ten Kate MT, Bakker-Woudenberg IAJM, and Verbrugh HA. Liposomal amphotericin B (AmBisome®) reduces dissemination of infection as compared to amphotercin B deoxycholate (Fungizone®) in a newly developed animal model of one-sided pulmonary aspergillosis. J Antimicrob Chemother 1996; 38: 215–225.Google Scholar
- 10.Van Etten EWM, Stearne-Cullen LET, Snijders SV, Verbrugh HA, BakkerWoudenberg IAJM. Efficacy of pegylated long circulating amphotericin B-liposomes in the treatment of pulmonary aspergillosis in leukopenic rats. (Manuscript in preparation).Google Scholar